Literature DB >> 3582468

A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients.

K Sabanathan, C M Castleden, H K Adam, J Ryan, T J Fitzsimons.   

Abstract

Six normal young and six normal elderly volunteers and six elderly hypertensive patients took part in an acute and chronic dose study of a combination capsule containing atenolol (50 mg), hydrochlorothiazide (25 mg) and amiloride (2.5 mg) designed for the treatment of hypertension. No difference in any of the drug pharmacokinetic parameters could be detected between the hypertensives and the normal elderly subjects. The bio-availability and the 24-h blood concentrations of all three drugs, half-life of atenolol and amiloride and the peak concentration of hydrochlorothiazide was significantly greater in the elderly. The 24-h blood concentrations of atenolol and hydrochlorothiazide did not alter with chronic dosing, but amiloride concentrations were significantly higher at this time in all groups. A significant fall in the blood pressure was observed in the hypertensive group. Heart rate fell more in the normal and hypertensive elderly subjects than in the young. The combination has shown to be an effective and well tolerated antihypertensive in the elderly patient with a 24-h duration of action.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3582468     DOI: 10.1007/bf00609957

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Metabolism of atenolol in man.

Authors:  P R Reeves; J McAinsh; D A McIntosh; M J Winrow
Journal:  Xenobiotica       Date:  1978-05       Impact factor: 1.908

2.  Renal excretion of drugs in the elderly.

Authors:  J M Hansen; J Kampmann; H Laursen
Journal:  Lancet       Date:  1970-05-30       Impact factor: 79.321

3.  Comparative pharmacokinetic profiles of metoprolol and chlorthalidone administered alone or in combination to healthy volunteers.

Authors:  J Godbillon; A Gerardin; V A John; W Theobald
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Atenolol disposition in young and elderly subjects.

Authors:  P C Rubin; P J Scott; K McLean; A Pearson; D Ross; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

5.  Bioavailability in man of atenolol and chlorthalidone from a combination formulation.

Authors:  J McAinsh; W Bastain; J Young; J D Harry
Journal:  Biopharm Drug Dispos       Date:  1981 Apr-Jun       Impact factor: 1.627

6.  The gas chromatographic determination of atenolol in biological samples.

Authors:  B Scales; P B Copsey
Journal:  J Pharm Pharmacol       Date:  1975-06       Impact factor: 3.765

7.  Pharmacokinetics of hydrochlorothiazide in relation to renal function.

Authors:  C Niemeyer; G Hasenfuss; U Wais; H Knauf; M Schäfer-Korting; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.

Authors:  A Roux; A Le Liboux; B Delhotal; J Gaillot; B Flouvat
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Pharmacokinetics of hydrochlorothiazide in patients with congestive heart failure.

Authors:  B Beermann; M Groschinsky-Grind
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

10.  Bioavailability and disposition of metoprolol and hydrochlorothiazide combined in one tablet and of separate doses of hydrochlorothiazide.

Authors:  L Jordö; G Johnsson; P Lundborg; B A Persson; C G Regärdh; O Rönn
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

View more
  15 in total

Review 1.  Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.

Authors:  A A Mangoni; S H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

2.  Column-switching high-performance liquid chromatographic (HPLC) determination of hydrochlorothiazide in rat, dog, and human plasma.

Authors:  B S Kuo; A Mandagere; D R Osborne; K K Hwang
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

Review 3.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol.

Authors:  E S Dimenäs; C G Dahlöf; B Heibel; R G Moore; B K Olofsson; G E Westergren; P W Lücker
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Age and sex-related differences in dose-dependent hemodynamic response to landiolol hydrochloride during general anesthesia.

Authors:  Ju Mizuno; Ikuto Yoshiya; Takeshi Yokoyama; Yoshitsugu Yamada; Hideko Arita; Kazuo Hanaoka
Journal:  Eur J Clin Pharmacol       Date:  2007-01-09       Impact factor: 2.953

Review 6.  Mechanisms of altered renal sodium handling in age-related hypertension.

Authors:  Alissa A Frame; Richard D Wainford
Journal:  Am J Physiol Renal Physiol       Date:  2018-02-14

Review 7.  Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.

Authors:  R W Piepho; K J Fendler
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 8.  Age-related changes in the gastrointestinal system. Effects on drug therapy.

Authors:  F L Iber; P A Murphy; E S Connor
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

9.  Amiloride disposition in geriatric patients: importance of renal function.

Authors:  A Somogyi; D Hewson; M Muirhead; F Bochner
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

Review 10.  Adverse drug reactions. An overview of special considerations in the management of the elderly patient.

Authors:  L A Brawn; C M Castleden
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.